Market Cap
$41.3M
PDSB
PDS Biotechnology Corp
$0.7366 ▲ +4.33%
Prev close $0.7060Market cap$41.3M
ConsensusStrong Buy
12-mo target$4.75 (+543.6%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)4 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on PDSB right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Analyst Consensus
Strong Buy (89%)
Inst. Holders
36 funds
Inst. Value
$6.4M
Inst. Activity
4 buys / 1 sells
Social Sentiment
60° Warm
SEC Reports
14
Press Releases
3
Price chart 30d +247.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 25, 2026 short_volume
Sep 4, 2026 SEC Short Volume: PDSB — 58.7% short (1.5M / 2.6M)
Short: 1,531,197 | Exempt: 20,823 | TRF Vol: 2,607,157 | Short Ratio: 58.7% | Off-exchange volume (d
PDS Biotechnology amended its $6M promissory note with YA II PN, Ltd., tightening repayment terms: 100% of net proceeds
8-K — Impact 6/10
PDS Biotechnology Corp disclosed the resignation of CFO Lars Boesgaard, effective September 12, 2026, to pursue other pr
8-K — Impact 3/10
PDS Biotech reported Q2 2026 EPS of -$0.18, a 42.1% miss vs consensus of -$0.13, and announced a strategic refocus to pr
8-K — Impact 7/10
Jun 30, 2026 Inst.
MORGAN STANLEY — DOUBLED
313,922 shares ($276.6K)
Jun 30, 2026 Inst.
Apr 15, 2026 Press SUSQUEHANNA INTERNATIONAL GROUP, LLP — ADD
36,328 shares ($32.0K)
PDS Biotechnology announced preliminary data from a trial using its PDS01ADC technology, showing a 78% objective respons
Impact 8/10
PDS Biotechnology reported financial results for 2025 and provided a clinical update, including a Phase 3 trial amendmen
Impact 6/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
89% rate it Buy or better · 9 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 8, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 13, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Apr 15, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Aug 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jul 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Price targets
Where 2 covering analysts think PDSB trades over the next 12 months.
$4.75 +543.6% upside Strong Buy
Current$0.7380 Low$4.50 Median$4.75 High$5.00 2 analysts
$4.50$5.00
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +50.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
60°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 3 bullish, 6 bearish, 0 mixed, 5 neutral · avg impact 5.4/10.Plus 3 press releases.
BEARISH8-K6/10
PDS Biotechnology amended its $6M promissory note with YA II PN, Ltd., tightening repayment terms: 1
Sep 4, 2026
NEUTRAL8-K3/10
PDS Biotechnology Corp disclosed the resignation of CFO Lars Boesgaard, effective September 12, 2026
Aug 19, 2026
BEARISH8-K7/10
PDS Biotech reported Q2 2026 EPS of -$0.18, a 42.1% miss vs consensus of -$0.13, and announced a str
Aug 13, 2026
BEARISH8-K7/10
PDS Biotechnology announced a strategic refocus prioritizing PDS0301 in metastatic colorectal cancer
Aug 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 25, 2026
short_volume
Short Volume: PDSB — 58.7% short (1.5M / 2.6M)
Short: 1,531,197 | Exempt: 20,823 | TRF Vol: 2,607,157 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: PDSB — 55.5% short (1.9M / 3.5M)
Short: 1,938,491 | Exempt: 483,892 | TRF Vol: 3,490,694 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: PDSB — 55.1% short (3.1M / 5.6M)
Short: 3,103,350 | Exempt: 116,965 | TRF Vol: 5,637,122 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
fda
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients
Sep 16, 2026
short_volume
Short Volume: PDSB — 55.3% short (77.0M / 139.4M)
Short: 77,014,415 | Exempt: 1,350,510 | TRF Vol: 139,361,549 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.11 | $-0.11–$-0.11 | 42.1% | +5.7% | 1↑ 0↓ | $0.0B | 1 |
| Next Q | $-0.09 | $-0.09–$-0.09 | 35.7% | +25.0% | 1↑ 0↓ | $0.0B | 1 |
| Current FY | $-0.49 | $-0.49–$-0.49 | 33.8% | +1.3% | 1↑ 0↓ | $0.0B | 1 |
| Next FY | $-0.36 | $-0.40–$-0.30 | 25.9% | +22.1% | 1↑ 0↓ | $0.0B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.110 | — |
| 7d ago | $-0.110 | — |
| 30d ago | $-0.117 | +0.007 |
| 60d ago | $-0.117 | +0.007 |
| 90d ago | $-0.117 | +0.007 |
Institutional ownership
Which big funds own PDSB (from quarterly 13F filings) and who is adding or trimming.
36 institutional holders with $6.4M total value (7,248,394 shares) as of 2026-Q2. Top holders: ROYAL, VANGUARD, Quantinno. Net buying activity: 4 institutions added/increased vs 1 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| ROYAL BANK OF CANADA | 80 | $0.00 | 0.0% | DOUBLED +2380.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,699,315 | $1.5M | 23.4% | — |
| Quantinno Capital Management LP | 642,177 | $565.8K | 8.9% | — |
| Focus Partners Wealth | 642,177 | $565.8K | 8.9% | — |
| BlackRock, Inc. | 607,639 | $535.4K | 8.4% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 587,139 | $517.4K | 8.1% | ADD +26.9% |
| VANGUARD FIDUCIARY TRUST CO | 357,144 | $314.6K | 4.9% | — |
| CITADEL ADVISORS LLC | 323,801 | $285.3K | 4.5% | ADD +55.2% |
| Caption Management, LLC | 319,100 | $281.2K | 4.4% | — |
| MORGAN STANLEY | 313,922 | $276.6K | 4.3% | DOUBLED +7904.1% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 3,922 | 313,922 | +7904.1% | $276.6K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | ADD | 22,052 | 36,328 | +64.7% | $32.0K |
| RAYMOND JAMES FINANCIAL INC | DOUBLED | 10,236 | 33,819 | +230.4% | $29.8K |
| Federation des caisses Desjardins du Quebec | ADD | 14,800 | 19,800 | +33.8% | $17.4K |
| UBS Group AG | NEAR_EXIT | 56,004 | 11,121 | -80.1% | $9.8K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 520,398 | 660,228 | +26.9% | $399.5K |
| WELLS FARGO & COMPANY/MN | DOUBLED | 5,329 | 110,500 | +1973.6% | $66.9K |
| COMMONWEALTH EQUITY SERVICES, LLC | TRIM | 196,797 | 90,797 | -53.9% | $54.9K |
| UBS Group AG | NEAR_EXIT | 251,705 | 56,004 | -77.8% | $33.9K |
| SIMPLEX TRADING, LLC | NEAR_EXIT | 19,106 | 271 | -98.6% | $163.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 11 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 12, 2026 | CONN GREGORY | Chief Scientific Officer | AWARD | 150,000 | — | — |
| Jan 12, 2026 | Brown Spencer D. | Senior VP, General Counsel | AWARD | 300,000 | — | — |
| Jan 12, 2026 | Toutain Stephan | Chief Operating Officer | AWARD | 300,000 | — | — |
| Jan 12, 2026 | Shepard Kirk V. | Chief Medical Officer | AWARD | 300,000 | — | — |
| Jan 12, 2026 | Glover Stephen C. | Director | AWARD | 54,876 | — | — |
| Jan 12, 2026 | Freitag Gregory Gene | Director | AWARD | 54,876 | — | — |
| Jan 12, 2026 | Iliev Ilian | Director | AWARD | 54,876 | — | — |
| Jan 12, 2026 | BEDU-ADDO FRANK | President/CEO | AWARD | 548,782 | — | — |
| Jan 12, 2026 | Boesgaard Lars | Chief Financial Officer | AWARD | 300,000 | — | — |
| Jan 12, 2026 | Ali-Jackson Kamil | Director | AWARD | 54,876 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PDSB.
Shares short
6,406,521
Settlement Sep 15, 2026
Change vs prior
+172.7%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈8.8%
Estimate — not % of float
All PDSB filing & press-release reports (17)
- 8-K reportSep 4, 2026
- 8-K reportAug 19, 2026
- 8-K reportAug 13, 2026
- 8-K reportAug 11, 2026
- EFFECT reportJul 22, 2026
- DEFA14A reportJul 3, 2026
- 8-K reportJun 15, 2026
- 8-K reportJun 15, 2026
- 8-K reportJun 2, 2026
- PRESS-RELEASE reportMay 13, 2026
- 8-K reportMay 1, 2026
- S-3/A reportApr 27, 2026
- 8-K reportApr 24, 2026
- 8-K reportApr 15, 2026
- PRESS-RELEASE reportApr 15, 2026
- PRESS-RELEASE reportMar 30, 2026
- PRESS-RELEASE reportMar 24, 2026